AbbVie Inc.

ABBVNYSEHealthcare● Active

$227.23

+$2.29(+1.02%)

Market Cap$401.5B

P/E Ratio—

52W High$244.81

52W Low$181.73

Avg Volume6.6M

Open$227.37

Beta0.31

Overview

AbbVie Inc. (ABBV) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ABBV · free cash flow · updated Jun 8, 2026

Core FCF metrics

ABBV · FCF · TTM · margin & CAGR

Free cash flow was $17.82B for FY2025 (fiscal year ending 2025-12-31), down 0.1% year-over-year The FCF margin was 29.1%. Five-year CAGR stands at +1.2%.

FY2025 Free Cash Flow$17.82B▼ -0.1% YoY

Trailing 12M (TTM)$20.86Btrailing 4 quarters sum

FCF Margin29.1%$17.82B ÷ revenue

3-Year CAGR-9.8%FY2022 → FY2025

5-Year CAGR+1.2%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ABBV · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$19.03B(1.21B)$17.82B▼ 0.1%29.1%

FY2024$18.81B(974M)$17.83B▼ 19.2%31.6%

FY2023$22.84B(777M)$22.06B▼ 9.0%40.6%

FY2022$24.94B(695M)$24.25B▲ +10.3%41.8%

FY2021$22.78B(787M)$21.99B▲ +31.0%39.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ABBV · P/FCF · FCF yield · FCF per share

AbbVie Inc. (ABBV) trades at a FCF yield of 5.20% and a price-to-free-cash-flow ratio of 19.4x. FCF per share stands at $11.72, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

5.20%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$11.72

TTM FCF ÷ Shares Outstanding

Price / FCF

x19.4

Share Price ÷ FCF per Share

EV / FCF (TTM)

x22.3

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ABBV · cash flow statement · operating / investing / financing

For FY2025, AbbVie Inc. generated $19.03B in operating cash flow and spent 1.21B in capital expenditures, yielding $17.82B in free cash flow.

Operating Activities

+$19.03B

Cash from core business operations

2025-12-31

Investing Activities

−$6.64B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$12.72B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($19.03B) − |CapEx| (1.21B) = FCF ($17.82B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ABBV vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

AbbVie Inc.YOU

ABBV

$17.82B-0.1%29.1%

90%

UnitedHealth Group Incorporated

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

AbbVie Inc. (ABBV) reported free cash flow of $17.82B for FY2025 (fiscal year ending 2025-12-31), down 0.1% year-over-year. The FCF margin was 29.1%.

Based on available data, AbbVie Inc. has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $24.25B in FY2022. The 5-year CAGR stands at +1.2%.

AbbVie Inc.'s FCF yield is 5.20% and price-to-FCF ratio is 19.4x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ABBV free cash flow · 8 questions

AbbVie Inc. free cash flow was $17.82B for FY2025, down 0.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $20.86B.

ABBV free cash flowABBV FCFABBV FCF 2025ABBV free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · AbbVie Inc. · AbbVie Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026